Cassava Sciences ( (SAVA) ) has issued an announcement.
Cassava Sciences, Inc., a biotech firm dedicated to Alzheimer’s treatment, has appointed Richard (Rick) Barry as its CEO after a comprehensive search. Barry, who joined Cassava’s board in June 2021 and became Executive Chairman in July 2024, boasts a wealth of investment management and biotech sector experience. The company also announced the separation of the CEO and Chairman roles, appointing Dr. Claude Nicaise as Chairman to align with good governance practices. Barry’s commitment to transparency and ethical practices, coupled with his focus on advancing Alzheimer’s treatment, is highlighted as Cassava anticipates results from their Phase 3 trials of the drug simufilam.
For an in-depth examination of SAVA stock, go to TipRanks’ Stock Analysis page.
